Reuven Schore is running a clinical trial to test drugs called Bortezomib and Pravastatin to treat Leukemia. This study aims to monitor patients for relapse of the leukemia following allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in order to identify patients early in relapse, with a low burden of disease, when interventions may be more successful by monitoring of peripheral blood lineage specific chimerism. Once disease has been confirmed, patients will initiate a novel combination of bortezomib and pravastatin.
The drugs are Bortezomib and Pravastatin.
| Study Type : |
Interventional (Clinical Trial) |
| Estimated Enrollment : |
50 participants |
| Allocation: |
Non-Randomized |
| Intervention Model: |
Crossover Assignment |
| Masking: |
None (Open Label) |
| Primary Purpose: |
Treatment |
| Official Title: |
Pilot Study to Evaluate the Tolerability of Velcade (Bortezomib) and Pravastatin for the Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children |
| Actual Study Start Date : |
May 2015 |
| Estimated Primary Completion Date : |
July 2019 |
| Estimated Study Completion Date : |
August 2020 |
Contacts
| Contact: Maggie Holly |
202-476-5532 |
mholly@childrensnational.org |
| Contact: Reuven Schore, MD |
202-476-5875 |
rschore@childrensnational.org |
NCT Number
For enrollment please visit www.clinicaltrials.gov.
